Cancer Immunotherapy Channeled via Remote Control – Genetic Engineering & Biotechnology News
Reader’s Digest |
Cancer Immunotherapy Channeled via Remote Control
Genetic Engineering & Biotechnology News We’re a long way from controlling our immune systems as easily as we might change the channels on our televisions, but a new remote-control system, in the hands of clinicians, could enable the narrowcasting of immunotherapies. For example, cancer … Researchers develop a remote-controlled cancer immunotherapy systemDrug Target Review Minimally Invasive Cancer Therapies to Gain PrevalenceEdition Truth |
Business Insider |
The hottest thing in cancer drug development is a takeover target again — here’s what you need to know about it
Business Insider Instead of getting a better, updated therapy for a disease every decade or so, we might begin to see second-generation cell therapies in a few years. One challenge these therapies still face is how toxic they can be. CAR–T’s side effects can be deadly … CAR T-Cell Therapy Gets Priority Review for Lymphoma TreatmentCuretoday.com FDA Grants Priority Review to CAR T-Cell Therapy Tisagenlecleucel for DLBCLwww.oncnursingnews.com/ Speedy EU, US review for Novartis’ CAR–T therapy KymriahPharmaTimes Canada NewsWire (press release) –The FINANCIAL –WHTC all 14 news articles » |
Massive |
How scientists are mapping the building blocks of life
Massive This is not biology’s first attempt at an ambitious, “man-on-the-moon” project, and past initiatives have proven tremendously beneficial to science. The impact of the Human Genome Project (HGP) cannot be understated, for example: it has accelerated the … |
Genetic Literacy Project |
6 amazing medical advancements to expect in 2018
CNBC “If you look at cancer, we know the majority of cancer starts with a DNA defect,” Dr. Roizen says. “And that DNA defect can be corrected or ameliorated. Say you have a family who has in vitro fertilization; they will examine the genes of the embryo … Report: Price for blindness gene therapy Luxturna is ‘four times too high’ at $850000Genetic Literacy Project |
Genetic Literacy Project |
At $850000, price for new childhood blindness gene therapy four times too high, analysis says
Pharmacy Today, American Pharmacists Association, pharmacist.com voretigene neparvovec-rzyl (Luxturna—Spark Therapeutics), the first-of-its-kind gene therapy for a form of childhood blindness caused by a mutation in the RPE65 gene, is approximately four times too high for the value the drug provides. In a new … Report: Price for blindness gene therapy Luxturna is ‘four times too high’ at $850000Genetic Literacy Project 6 big medical advancements to expect in 2018CNBC |
Genetic Literacy Project |
Report: Price for blindness gene therapy Luxturna is ‘four times too high’ at $850000
Genetic Literacy Project The report from the Institute for Clinical and Economic Review focused on the medicine Luxturna, the first-of-its-kind gene therapy approved for the U.S. market and the most expensive medicine by list price. It is the latest flashpoint in the debate … At $850000, price for new childhood blindness gene therapy four times too high, analysis saysPharmacy Today, American Pharmacists Association, pharmacist.com 6 amazing medical advancements to expect in 2018CNBC Spark Therapeutics: Challenges Posed By SuccessSeeking Alpha |